{
"raw_text": "{\n  \"base_id\": \"base_anticoagulation_0240\",\n  \"domain\": \"anticoagulation\",\n  \"demographics\": {\n    \"age_group\": \"55-64\",\n    \"sex\": \"M\"\n  },\n  \"comorbidities\": [\n    \"atrial_fibrillation\",\n    \"hypertension\"\n  ],\n  \"meds\": [\n    {\n      \"name\": \"warfarin\",\n      \"dose\": \"5mg\",\n      \"freq\": \"daily\"\n    },\n    {\n      \"name\": \"aspirin\",\n      \"dose\": \"81mg\",\n      \"freq\": \"daily\"\n    }\n  ],\n  \"vitals\": {\n    \"BP_sys\": 128,\n    \"HR\": 72\n  },\n  \"labs\": {\n    \"INR\": 2.2,\n    \"Cr\": 1.0,\n    \"eGFR\": 85\n  },\n  \"allergies\": [],\n  \"pregnancy_flag\": false,\n  \"notes\": \"Synthetic case 241. Domain: anticoagulation. Age group 55-64, sex M. No real patient data.\",\n  \"assessment\": \"The patient is a male aged 55-64 with atrial fibrillation and hypertension on warfarin and aspirin therapy. His INR is within the therapeutic range (2.0-3.0), blood pressure and heart rate are controlled, and renal function is normal. Concomitant use of aspirin with warfarin increases bleeding risk; clinical justification for dual therapy should be confirmed. Regular monitoring of INR and bleeding signs is advised.\",\n  \"recommendations\": [\n    \"Continue warfarin therapy with regular INR monitoring to maintain therapeutic range.\",\n    \"Evaluate the indication for combined aspirin therapy with warfarin due to increased bleeding risk; consider discontinuation if no strong indication (e.g., recent coronary stenting).\",\n    \"Continue blood pressure management for hypertension.\",\n    \"Monitor for signs of bleeding or adverse effects from anticoagulation therapy.\"\n  ]\n}",
"model_id": "openai",
"version": "gpt-4.1-mini",
"prompt_tokens": 344,
"completion_tokens": 420,
"latency_seconds": 5.786370699992403
}